Payment overview · 2025
General Payments
$2,834.30
124 reported records · 25 companies
Healthcare provider profile · identity verified
Channa Perera, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WEST HAVEN, CT · NPI 1467458216
Verified facts
What the public records show
CMS Open Payments records show Channa Perera, M.D. received $2,834.30 in general payments during 2025 across 124 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Lokelma, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Lokelma by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 504 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Lantus by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $649.51 | 22.9% | 24 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $318.08 | 11.2% | 17 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $286.86 | 10.1% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $165.69 | 5.8% | 8 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $150.08 | 5.3% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $144.06 | 5.1% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $143.76 | 5.1% | 7 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $139.99 | 4.9% | 6 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $110.13 | 3.9% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $108.52 | 3.8% | 5 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $107.19 | 3.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.69 | 2.7% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $66.14 | 2.3% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $65.16 | 2.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $64.67 | 2.3% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $40.64 | 1.4% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $40.54 | 1.4% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $29.85 | 1.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $27.12 | 1.0% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $19.11 | 0.7% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.21 | 0.6% | 1 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $16.08 | 0.6% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.86 | 0.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.75 | 0.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.61 | 0.6% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,720.31 | 122 |
| Education | $113.99 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $329.68 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $307.55 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $275.84 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $228.57 | 12 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $220.81 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $206.87 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $158.80 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $144.06 | 10 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $139.99 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $124.08 | 6 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $110.13 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $108.52 | 5 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $107.19 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $100.44 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $100.44 | 5 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $90.59 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $66.14 | 3 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $65.16 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $59.49 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $56.49 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $54.50 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.82 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $44.47 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $40.64 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $40.64 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $40.54 | 2 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $35.01 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $29.85 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $28.85 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.12 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $27.12 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $23.28 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.97 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.61 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 41 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 504 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 96 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
39 | 13 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
41 | 40 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
96 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
90 | 28 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
504 | 53 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 580 | 115 |
| Eliquis | Apixaban | 504 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 350 | 75 |
| Gabapentin | Gabapentin | 334 | 64 |
| Trazodone Hcl | Trazodone Hcl | 329 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 325 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 261 | 59 |
| Metformin Hcl | Metformin Hcl | 213 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 210 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 205 | 48 |
| Furosemide | Furosemide | 180 | 46 |
| Losartan Potassium | Losartan Potassium | 170 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 151 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 144 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 124 | 16 |
| Mirtazapine | Mirtazapine | 109 | 31 |
| Carvedilol | Carvedilol | 105 | 18 |
| Prednisone | Prednisone | 105 | 23 |
| Potassium Chloride | Potassium Chloride | 100 | 22 |
| Lisinopril | Lisinopril | 99 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 96 | 19 |
| Allopurinol | Allopurinol | 90 | 16 |
| Ozempic | Semaglutide | 90 | 28 |
| Gemtesa | Vibegron | 89 | suppressed |
| Levetiracetam | Levetiracetam | 89 | 16 |
| Donepezil Hcl | Donepezil Hcl | 81 | 18 |
| Famotidine | Famotidine | 77 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 21 |
| Sertraline Hcl | Sertraline Hcl | 72 | 19 |
| Memantine Hcl | Memantine Hcl | 71 | 15 |
| Metformin Hcl Er | Metformin Hcl | 71 | 21 |
| Myrbetriq | Mirabegron | 70 | suppressed |
| Jardiance | Empagliflozin | 67 | suppressed |
| Omeprazole | Omeprazole | 64 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | 13 |
| Finasteride | Finasteride | 63 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 13 |
| Torsemide | Torsemide | 63 | suppressed |
| Xarelto | Rivaroxaban | 61 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 20 |
| Olanzapine | Olanzapine | 59 | suppressed |
| Januvia | Sitagliptin Phosphate | 58 | 11 |
| Risperidone | Risperidone | 58 | 15 |
| Tradjenta | Linagliptin | 56 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 55 | 11 |
| Lorazepam | Lorazepam | 54 | 22 |
| Methenamine Hippurate | Methenamine Hippurate | 54 | suppressed |
| Latanoprost | Latanoprost | 53 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 50 | suppressed |
| Entresto | Sacubitril/Valsartan | 50 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 49 | 21 |
| Budesonide Ec | Budesonide | 46 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 18 |
| Tramadol Hcl | Tramadol Hcl | 46 | 20 |
| Valsartan | Valsartan | 46 | 19 |
| Ketoconazole | Ketoconazole | 45 | 26 |
| Lactulose | Lactulose | 45 | 15 |
| Meloxicam | Meloxicam | 44 | 24 |
| Trulicity | Dulaglutide | 42 | 17 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 41 | 40 |
| Divalproex Sodium | Divalproex Sodium | 41 | 12 |
| Linzess | Linaclotide | 39 | 13 |
| Lokelma | Sodium Zirconium Cyclosilicate | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 29 |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Lidocaine | Lidocaine | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Mupirocin | Mupirocin | 37 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 36 | suppressed |
| Simvastatin | Simvastatin | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | 13 |
| Dapagliflozin | Dapagliflozin Propanediol | 35 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 35 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 35 | 12 |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Methocarbamol | Methocarbamol | 34 | suppressed |
| Clonazepam | Clonazepam | 33 | 13 |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Enulose | Lactulose | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 20 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 30 | suppressed |
| Digoxin | Digoxin | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 16 |
| Alprazolam | Alprazolam | 28 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 12 |
| Glimepiride | Glimepiride | 27 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 24 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Scopolamine | Scopolamine | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 22 | 13 |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | 14 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Acetylcysteine | Acetylcysteine | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 19 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 18 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 18 | 12 |
| Enoxaparin Sodium | Enoxaparin Sodium | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 15 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Nystatin | Nystatin | 17 | 12 |
| Acetic Acid | Acetic Acid | 16 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Budesonide | Budesonide | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Cyclosporine | Cyclosporine | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Entecavir | Entecavir | 14 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Atovaquone | Atovaquone | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Budesonide Dr | Budesonide | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Febuxostat | Febuxostat | 13 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 13 | 11 |
| Metolazone | Metolazone | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Rebif | Interferon Beta-1a/Albumin | 13 | suppressed |
| Travoprost | Travoprost | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Clozapine | Clozapine | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 12 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Lamivudine Hbv | Lamivudine | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Tivicay | Dolutegravir Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,834.30 · 124 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, AUSTEDO XR, BREZTRI, CAPLYTA, CAPVAXIVE, CONTRAVE, Cologuard Collection Kit, ELIQUIS, FARXIGA, FASENRA, GARDASIL 9, GLASSIA, IBSRELA, INGREZZA, INSPIRE, LOKELMA, MOUNJARO, NUCALA, NURTEC ODT, NUZYRA, OTEZLA, QULIPTA, REPATHA, REXULTI, SHINGRIX, TEZSPIRE, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, WatchPATONE, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error